Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 10/2003

01-10-2003 | Original Article

Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients

Authors: L. G. Durrant, M. A. Chapman, D. J. Buckley, I. Spendlove, R. A. Robins, N. C. Armitage

Published in: Cancer Immunology, Immunotherapy | Issue 10/2003

Login to get access

Abstract

This study prospectively correlated the level of expression of CD55 on tumours with 7-year survival in 136 colorectal cancer patients. Patients with tumours expressing high levels of CD55 had a significantly worse survival (24%) than patients with low CD55 levels (50%, p<0.02). A similar difference was seen for patients (Duke's B or C) with a high risk of recurrence (29% vs 58%, p<0.05). Furthermore, there was a progressive deterioration in prognosis with increasing antigen expression (p=0.01). It remains unclear if CD55 is overexpressed by tumours to protect them from complement or if it is related to the recent observation that CD55 is a ligand for the T-cell activation antigen CD97. However, it is a marker of aggression, as colorectal cancer patients whose tumours overexpress CD55 have a significantly reduced 7-year survival.
Literature
1.
Amin S, Robins RA, Maxwell-Armstrong C, Scholefield J, Durrant LG (2000) Vaccine induced apoptosis: a novel clinical trial endpoint? Cancer Res 60(12):3132–3136
2.
Armitage NC, Perkins AC, Pimm MV, Farrands PA, Baldwin RW, Hardcastle JD (1984) Localization of an anti-tumour monoclonal antibody (791T/36) in gastrointestinal tumors. Br J Surg 71(6):407–412PubMed
3.
Bosari S, Viale G, Bossi P, Maggioni M, Coggi G, Murray JJ, Lee AK (1994) Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal carcinomas. J Natl Cancer Inst 86:681–687PubMed
4.
Chu KC, Tarone RE, Chow W et al (1994) Temporal patterns in colorectal cancer incidence, survival and mortality from 1950 through 1990. J Natl Cancer Inst 86:997–1006PubMed
5.
Davis LS, Patel SS, Atkinson JP, Lipsky PE (1988) Decay accelerating factor functions as a signal transducing molecule for human T cells. J Immunol 141:2246–2252PubMed
6.
Durrant LG, Armstrong CM, Buckley D, Amin S, Robins RA, Carmichael JC et al (2000) A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55. Clin Cancer Res 62(2):422–430
7.
Durrant LG, Robins RA, Baldwin RW (1989) Flow cytometric screening of monoclonal antibodies for drug or toxin targeting to human cancer. J Natl Cancer Inst 81:688–695PubMed
8.
Hamann J, Vogel B, Vanschijndel GMW, Vanlier RAW (1996) The 7-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF) J Exp Med 184(3):1185–1189
9.
Li L, Spendlove I, Morgan J, Durrant LG (2000) CD55 is overexpressed in the tumour environment. Br J Cancer 84(1):80–86
10.
Lindemann F, Schlimok G, Dirschedl P et al (1992) Prognostic significance of micrometastatic tumour cells in the bone marrow of colorectal cancer patients. Lancet 340:685–689PubMed
11.
Maxwell-Armstrong CA, Durrant LG, Robins RA, Galvin AM, Scholefield JH, Hardcastle JD (1999) Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotype monoclonal antibody 105AD7. Gut 45:593–598PubMed
12.
Moertel CG, Fleming TR, Macdonald JS et al (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon cariconmas. N Engl J Med 322:352–358PubMed
13.
Morgan J, Spendlove I, Durrant LG (2002) The role of CD55 in protecting the tumour environment from complement attack. Tissue Antigens 60(3):213–223CrossRefPubMed
14.
Nicholson-Weller A, Wang C (1994) Structure and function of decay-accelerating factor CD55. J Lab Clin Med 123(4):485–491PubMed
15.
Spendlove I, Li L, Carmichael J, Durrant LG (1999) Decay accelerating factor (CD55): a target for cancer vaccines? Cancer Res 59(10):2282–2286
16.
Starzynska T, Marsh PJ, Scholfield PF et al (1994) Prognostic significance of 5T4 oncofetal antigen expression in colorectal adenocarcinomas. Br J Cancer 69:899–902
Metadata
Title
Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients
Authors
L. G. Durrant
M. A. Chapman
D. J. Buckley
I. Spendlove
R. A. Robins
N. C. Armitage
Publication date
01-10-2003
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 10/2003
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-003-0402-y

Other articles of this Issue 10/2003

Cancer Immunology, Immunotherapy 10/2003 Go to the issue

Original Article

Tumor immunotherapy by converting tumor cells to MHC class II–positive, Ii protein–negative phenotype

Original Article

Lymphocyte subsets and T h 1/T h 2 immune responses in patients with adenocarcinoma of the oesophagus or oesophagogastric junction: relation to pTNM stage and clinical outcome

Review

Optimizing dendritic cell–based anticancer immunotherapy: maturation state does have clinical impact

Original Article

A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers

Original Article

The effects of αGalCer-induced TCRVα24 Vβ11+ natural killer T cells on NK cell cytotoxicity in umbilical cord blood

Symposium Series

Development of Therapeutic Cancer Vaccines Conference, 27–29 April 2003
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits